Sam Brusco, Associate Editor07.10.23
Fresenius Medical Care (FMC) has named Martin Fischer to succeed Helen Giza, who was promoted to the CEO role at FMC in 2022, as its new chief financial officer (CFO).
Fischer was head of finance for Siemens Healthineers’ diganostics division since 2019. Before that, he headed Healthineers’ board office and organizations function for the company’s initial public offering in March 2018. Prior to that, he held a variety of international operational and finance positions in Siemens.
Fischer told the press, "There are great challenges ahead of us. I am convinced of the company's potential and look forward to realizing it together with the global team of Fresenius Medical Care. I am excited to bring my experience and expertise to support the company's transformation."
Helen Giza added, "Martin Fischer has proven that he can successfully drive fundamental change in organizations. In our organizational transformation and turnaround management, we will benefit from his finance and healthcare expertise. Martin will be an important contributor to the execution of our strategy in unlocking value as the leading kidney care company."
Fischer was head of finance for Siemens Healthineers’ diganostics division since 2019. Before that, he headed Healthineers’ board office and organizations function for the company’s initial public offering in March 2018. Prior to that, he held a variety of international operational and finance positions in Siemens.
Fischer told the press, "There are great challenges ahead of us. I am convinced of the company's potential and look forward to realizing it together with the global team of Fresenius Medical Care. I am excited to bring my experience and expertise to support the company's transformation."
Helen Giza added, "Martin Fischer has proven that he can successfully drive fundamental change in organizations. In our organizational transformation and turnaround management, we will benefit from his finance and healthcare expertise. Martin will be an important contributor to the execution of our strategy in unlocking value as the leading kidney care company."